Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

Study of APR-1051 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06260514

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06260514. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-Label, Multicenter, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APR-1051 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

Study identification

NCT ID
NCT06260514
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Aprea Therapeutics
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 13, 2024 (Actual)
Primary completion
Jun 2027 (Estimated)
Completion
Jun 2028 (Estimated)
Last update posted
Nov 17, 2026

2024 – 2028

United States locations

U.S. sites
8
U.S. states
4
U.S. cities
6
Facility City State ZIP Site status
Rutgers Cancer Institute New Brunswick New Jersey 08903 Recruiting
University Hospitals, Cleveland Medical Center Cleveland Ohio 44106 Recruiting
Cleveland Clinic Cleveland Ohio 44195 Recruiting
MD Anderson Cancer Center (MDACC) Houston Texas 77030 Recruiting
NEXT Oncology- Houston Houston Texas 77054 Recruiting
NEXT Oncology -Dallas Irving Texas 75039 Recruiting
NEXT Oncology -San Antonio San Antonio Texas 78229 Recruiting
NEXT Oncology -Virginia Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06260514, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.